The global CRO market is dominated by names built for scale - IQVIA, Parexel, ICON, Fortrea, PPD. They are enormous, capable, and largely oriented around the biggest pharmaceutical sponsors. HiRO has chosen not to compete on their terms. Its differentiation rests on three deliberate choices: stay mid-sized, stay integrated, and stay genuinely local in each market it enters.
Being integrated means a sponsor deals with one partner and one contract rather than stitching together a dozen vendors. Being genuinely local means real offices and real regulator relationships in each country - the difference between promising global reach and actually holding the keys to ten front doors. And staying mid-sized means a small biotech is a priority client, not a rounding error.
Where HiRO fits in the market, then, is the cross-border lane between Asia and the West - a corridor of growing biotech activity that the mega-CROs serve but don't specialize in. By pairing trial execution with strategic consulting and even investor introductions, HiRO addresses the biotech customer's whole problem, not just the slice inside a standard statement of work.
That positioning is also its business model: fee-for-service clinical development contracts, flexible FSP engagements, and strategic consulting, with growth accelerated by acquiring regional CROs to add capability and geography. Three acquisitions in roughly four years turned a 2020 startup into a company operating across ten countries.
